Biogen Inc. (BIIB) Q2 2013 Earnings Results

Biogen Beats on EPS, Stock Up 0.38%

Biogen's strong EPS performance indicates better-than-expected profitability, which likely contributed to the slight increase in stock price. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors may be encouraged by the positive EPS surprise but will be looking for more clarity in upcoming reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.30	N/A	+25.55%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in their product pipeline and market position. They acknowledged external pressures but remain focused on growth.

Management highlighted the strong performance in their key therapeutic areas.

They emphasized ongoing commitment to innovation despite market challenges.

Biogen Beats on EPS, Stock Up 0.38%

Key numbers

Management commentary

Biogen Inc.

More earnings this week

Biogen Beats on EPS, Stock Up 0.38%

Key numbers

Management commentary